Literature DB >> 7559911

Autologous human B-cell immune response to pulmonary adenocarcinomatous polymorphic epithelial mucin.

J Xiang1, T Moyana, A Maksymiuk.   

Abstract

In order to investigate whether a B-cell immune response to the polymorphic epithelial mucin (PEM) is present in adenocarcinomatous patients, peripheral blood lymphocytes from 20 patients with adenocarcinomas from various sites were fused with the mouse-human heteromyeloma cell line SHM-D33. One IgM(K) monoclonal antibody derived from peripheral blood lymphocytes of a patient with a lung adenocarcinoma was generated with binding reactivity for bovine submaxillary mucin (BSM). The latter is one of the PEMs, and it contains a large amount of the tumor-associated sialosyl-Tn epitope. The generated antibody was designated KMD-2. Immunohistological studies on various tissues showed that KMD-2 reacted with 6/6 colorectal adenocarcinomas and 4/6 pulmonary adenocarcinomas. The antibody also displayed a slight degree of cross-reactivity with a limited number of normal tissues, especially those that elaborate mucin. Our data show that an autologous antibody response in the form of IgM to the immunosuppressive PEM is present in some adenocarcinomatous patients. The data also suggest that the KMD-2 (IgM/K) antibody may be of clinical importance for diagnostic purposes of adenocarcinomatous disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559911     DOI: 10.1007/bf01541735

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  20 in total

Review 1.  Lymphocyte responses and cytokines.

Authors:  W E Paul; R A Seder
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

2.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.

Authors:  S J Gendler; C A Lancaster; J Taylor-Papadimitriou; T Duhig; N Peat; J Burchell; L Pemberton; E N Lalani; D Wilson
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

3.  Carbohydrate structures of bovine submaxillary mucin.

Authors:  T Tsuji; T Osawa
Journal:  Carbohydr Res       Date:  1986-08-15       Impact factor: 2.104

4.  Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

Authors:  E van de Wiel-van Kemenade; M J Ligtenberg; A J de Boer; F Buijs; H L Vos; C J Melief; J Hilkens; C G Figdor
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

5.  Characterization of monoclonal antibodies to carcinoembryonic antigen with increased tumor specificity.

Authors:  S Jothy; S A Brazinsky; M Chin-A-Loy; A Haggarty; M J Krantz; M Cheung; A Fuks
Journal:  Lab Invest       Date:  1986-01       Impact factor: 5.662

6.  Antibody-guided diagnosis and therapy of malignant lesions.

Authors:  H P Kalofonos; S Stewart; A A Epenetos
Journal:  Int J Cancer Suppl       Date:  1988

7.  Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2----6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope.

Authors:  T Kjeldsen; H Clausen; S Hirohashi; T Ogawa; H Iijima; S Hakomori
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

8.  Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA).

Authors:  P Y Fung; B M Longenecker
Journal:  Cancer Res       Date:  1991-02-15       Impact factor: 12.701

Review 9.  Mucins: structure, function, and associations with malignancy.

Authors:  P L Devine; I F McKenzie
Journal:  Bioessays       Date:  1992-09       Impact factor: 4.345

10.  Production and characterization of a tumor-specific monoclonal antibody ACT19 recognizing an epitope distinctive from sialosyl-Tn on the TAG72 antigen.

Authors:  J Xiang; T Moyana; Z Chen; W Han; T Ping; E Li
Journal:  Tumori       Date:  1993-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.